JPWO2021247426A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021247426A5
JPWO2021247426A5 JP2022574199A JP2022574199A JPWO2021247426A5 JP WO2021247426 A5 JPWO2021247426 A5 JP WO2021247426A5 JP 2022574199 A JP2022574199 A JP 2022574199A JP 2022574199 A JP2022574199 A JP 2022574199A JP WO2021247426 A5 JPWO2021247426 A5 JP WO2021247426A5
Authority
JP
Japan
Prior art keywords
chain
seq
sequence
hcdr1
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022574199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528416A (ja
JP7767322B2 (ja
JP2023528416A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/034947 external-priority patent/WO2021247426A1/en
Publication of JP2023528416A publication Critical patent/JP2023528416A/ja
Publication of JP2023528416A5 publication Critical patent/JP2023528416A5/ja
Publication of JPWO2021247426A5 publication Critical patent/JPWO2021247426A5/ja
Priority to JP2025182305A priority Critical patent/JP2026053316A/ja
Application granted granted Critical
Publication of JP7767322B2 publication Critical patent/JP7767322B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022574199A 2020-06-04 2021-05-28 抗ａｂｃｇ２抗体及びそれらの使用 Active JP7767322B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025182305A JP2026053316A (ja) 2020-06-04 2025-10-29 抗ａｂｃｇ２抗体及びそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063034806P 2020-06-04 2020-06-04
US63/034,806 2020-06-04
PCT/US2021/034947 WO2021247426A1 (en) 2020-06-04 2021-05-28 Anti-abcg2 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025182305A Division JP2026053316A (ja) 2020-06-04 2025-10-29 抗ａｂｃｇ２抗体及びそれらの使用

Publications (4)

Publication Number Publication Date
JP2023528416A JP2023528416A (ja) 2023-07-04
JP2023528416A5 JP2023528416A5 (https=) 2024-06-04
JPWO2021247426A5 true JPWO2021247426A5 (https=) 2024-06-04
JP7767322B2 JP7767322B2 (ja) 2025-11-11

Family

ID=76601796

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022574199A Active JP7767322B2 (ja) 2020-06-04 2021-05-28 抗ａｂｃｇ２抗体及びそれらの使用
JP2025182305A Pending JP2026053316A (ja) 2020-06-04 2025-10-29 抗ａｂｃｇ２抗体及びそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025182305A Pending JP2026053316A (ja) 2020-06-04 2025-10-29 抗ａｂｃｇ２抗体及びそれらの使用

Country Status (7)

Country Link
US (1) US20230212305A1 (https=)
EP (1) EP4161650A1 (https=)
JP (2) JP7767322B2 (https=)
CN (1) CN116323662A (https=)
AU (1) AU2021284240A1 (https=)
CA (1) CA3182472A1 (https=)
WO (1) WO2021247426A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies
WO2025222167A1 (en) * 2024-04-19 2025-10-23 Zb17 Llc Methods of treatment
WO2025222168A1 (en) * 2024-04-19 2025-10-23 Zb17 Llc Methods of treatment
WO2025222170A1 (en) * 2024-04-19 2025-10-23 Zb17 Llc Methods of treatment

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
TW197439B (https=) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
WO1993010076A1 (en) 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
JPH08500973A (ja) 1992-05-21 1996-02-06 ザ ペン ステイト リサーチ ファウンデーション タキソール、関連タキサン及び他の新規な抗癌／抗ウイルス性化合物原料としてのイチイ培養組織
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
US6063621A (en) * 1992-10-27 2000-05-16 Queen's University At Kingston Antibodies to a multidrug resistance protein
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
WO1998008833A1 (en) 1996-08-26 1998-03-05 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
EP0961619A4 (en) 1996-09-27 2001-09-26 Bristol Myers Squibb Co HYDROLYSABLE DRUGS FOR THE RELEASE OF ANTI-CANCER DRUGS IN METASTATIC CELLS
AU4966597A (en) 1996-11-19 1998-06-10 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
IL133585A0 (en) 1997-06-20 2001-04-30 Baker Norton Pharma Soluble prodrugs of paclitaxel
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
WO1999018113A1 (fr) 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
WO2003035685A1 (en) * 2001-10-24 2003-05-01 Solvo Biotechnology Inc. Use of a half-transporter protein of the abcg-family for selecting cells and in gene therapy
EP3023437A1 (en) * 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
CN110655582B (zh) * 2015-01-08 2022-12-16 江苏康宁杰瑞生物制药有限公司 具有共同轻链的双特异性抗体或抗体混合物
CN106432490B (zh) * 2016-09-14 2020-01-07 北京大学 一种abcg2单克隆抗体及其用途

Similar Documents

Publication Publication Date Title
JP2020501531A5 (https=)
RU2018124602A (ru) Новые анти-pd-l1 антитела
JPWO2019129221A5 (https=)
CN110536903A (zh) 抗ox40抗体及其用途
CN115605511A (zh) 抗tigit的抗体、其制备方法和应用
JP2026041845A5 (https=)
JP2022122865A5 (https=)
CN110869390A (zh) 抗pd-l1抗体及其用途
JP2024001073A5 (https=)
JPWO2022256563A5 (https=)
CN111712521A (zh) Cd38蛋白抗体及其应用
JP2023116543A5 (https=)
JP2021523906A5 (https=)
JPWO2021247426A5 (https=)
JP2020533022A5 (https=)
JPWO2021224913A5 (https=)
JPWO2021133723A5 (https=)
JPWO2022173670A5 (https=)
JPWO2021116337A5 (https=)
JP2021531263A (ja) 抗ヒトｐｄ−ｌ１抗体とその使用
JPWO2021003297A5 (https=)
JPWO2020102555A5 (https=)
US20230242640A1 (en) ANTI-SIRPg Compounds
JPWO2021186427A5 (https=)
JPWO2023051683A5 (https=)